Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440646 | 0.85 | USP14 (0.44) | CYP3A4CYP2C19SCN9AUSP14PTGDR2 | |
| SCHEMBL2905366 | 0.84 | MAPT (0.41) | CYP3A4CYP2C19SCN9A | |
| SCHEMBL10293512 | 0.84 | SCN9A (0.34) | CYP3A4CYP2C19SCN9AUSP14PTGDR | |
| SCHEMBL394368 | 0.84 | CNR2 (0.39) | CYP3A4CYP2C19SCN9A | |
| SCHEMBL10293456 | 0.84 | ALDH1A1 (0.41) | CYP3A4CYP2C19SCN9A | |
| SCHEMBL3098417 | 0.84 | ALDH1A1 (0.37) | CYP3A4CYP2C19SCN9A | |
| SCHEMBL1173457 | 0.80 | SCN9A (0.51) | CYP3A4CYP2C19SCN9A | |
| SCHEMBL3073403 | 0.79 | USP14 (0.39) | CYP3A4CYP2C19SCN9AUSP14PTGDR | |
| SCHEMBL10293481 | 0.78 | SCN9A (0.54) | CYP3A4CYP2C19SCN9A | |
| SCHEMBL10082696 | 0.78 | SCN9A (0.37) | CYP3A4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
| WO-2009080836-A2 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | IDO1, HCCS, IDO2 | CYP3A4 84/4885CYP2C19 166/4885SCN9A 3800/4885 |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, IDO2 | CYP3A4 84/4885CYP2C19 166/4885SCN9A 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.